These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1870751)

  • 41. Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma.
    Wu CF; Shee JJ; Ho DR; Chen WC; Chen CS
    J Urol; 2004 Jan; 171(1):126-9. PubMed ID: 14665859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NTP Toxicology and Carcinogenesis Studies of o-Nitroanisole (CAS No. 91-23-6) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 May; 416():1-482. PubMed ID: 12616295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-invasive diagnostic tests for bladder cancer: a review of the literature.
    Bassi P; De Marco V; De Lisa A; Mancini M; Pinto F; Bertoloni R; Longo F
    Urol Int; 2005; 75(3):193-200. PubMed ID: 16215303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiological and cytological detection of renal pelvic transitional-cell carcinoma.
    Päivänsalo M; Merikanto J; Myllylä V; Hellström P; Kallionen M; Jalovaara P
    Rofo; 1990 Sep; 153(3):266-70. PubMed ID: 2171058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Analgesic nephropathy].
    Kramer P
    Med Klin; 1975 May; 70(20):889-95. PubMed ID: 1134426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.
    Johannes JR; Nelson E; Bibbo M; Bagley DH
    J Urol; 2010 Sep; 184(3):879-82. PubMed ID: 20643443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urine cytology in bladder tumors.
    Zein TA; Milad MF
    Int Surg; 1991; 76(1):52-4. PubMed ID: 2045253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinicopathological study on microscopic urinalysis as screening for malignant cells].
    Kawabe T; Kaneoka A; Koichi K; Murakami N; Kuroki T; Kinugasa M; Miyake S; Takasu K
    Rinsho Byori; 1989 Oct; 37(10):1167-72. PubMed ID: 2601075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.
    Kehinde EO; Al-Maghrebi M; Anim JT; Kapila K; George SS; Al-Juwaiser A; Memon A
    East Afr Med J; 2013 Jan; 90(1):19-27. PubMed ID: 26862626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How reliable is conventional urinary cytology in post-transplant patients?
    Reichelt O; Wunderlich H; Neiser G; Schubert J
    Urol Int; 2003; 71(2):176-7. PubMed ID: 12890956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Percutaneous management of renal pelvic urothelial tumors: long-term followup.
    Goel MC; Mahendra V; Roberts JG
    J Urol; 2003 Mar; 169(3):925-9; discussion 929-30. PubMed ID: 12576814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transitional cell carcinoma in dialysis patients.
    Ou JH; Pan CC; Lin JS; Tzai TS; Yang WH; Chang CC; Cheng HL; Lin YM; Tong YC
    Eur Urol; 2000 Jan; 37(1):90-4. PubMed ID: 10671792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
    Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
    Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Primary transitional cell carcinoma in situ of the renal pelvis: a case report].
    Ishibashi Y; Fukuoka H; Fujinami K; Tsuchiya F; Sakanishi S
    Hinyokika Kiyo; 1994 Sep; 40(9):829-32. PubMed ID: 7801846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term follow-up of transitional cell carcinoma of the bladder in childhood.
    Bujons A; Caffaratti J; Garat JM; Villavicencio H
    J Pediatr Urol; 2014 Feb; 10(1):167-70. PubMed ID: 24035638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.